Wanbury gets CEP for Dextromethorphan active pharmaceutical ingredient

09 Sep 2024 Evaluate

Wanbury has received Certificate of Suitability (CEP) from European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine. The global formulation market for Dextromethorphan is valued at $2,500 million for FY24, having grown by 7% over the past year. With the CEP certification, Wanbury is well positioned to initiate the commercial sales of this product in European markets.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.

Wanbury Share Price

242.70 3.50 (1.46%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.